[{"id":"kim-dong-wan","kind":"person","name":"Dong-Wan Kim","route":"/people/kim-dong-wan/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/people/asia-pacific.ts","type":"changed","fields":[{"field":"tldr","before":"\"A thoracic oncologist central to the ALK and ROS1 inhibitor trials, from crizotinib to brigatinib and beyond.\"","after":"\"Dong-Wan Kim is a thoracic oncologist central to the ALK and ROS1 inhibitor trials, from crizotinib to brigatinib and beyond.\""}]},{"id":"kim-dong-wan","kind":"person","name":"Dong-Wan Kim","route":"/people/kim-dong-wan/","commit":"9b4eb0eb88","date":"2026-09-08","author":"Jude Gomila","message":"Add Asia-Pacific, Canada, Brazil, and IARC/WHO people (91 person entities)","file":"src/data/people/asia-pacific.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"role"},{"field":"institutionId"},{"field":"institutions"},{"field":"specialisms"},{"field":"tldr"},{"field":"summary"},{"field":"profiles"},{"field":"papers"},{"field":"cancers"},{"field":"targets"},{"field":"drugs"}]}]